CSTR Grand Rounds: April 2021 Precision Medicine for Cardiovascular Prevention: My Personal Experience
Ended May 3, 2021
Sorry! The enrollment period is currently closed. Please check back soon.
Full course description
At the conclusion of this activity, learners will be able to:
- Describe current approach and role of risk assesment to guide intensity of lifestyle interventions and pharmacotherapy in cardiovascular prevention.
- Discuss genetic testing available and current role in CV prevention.
- Describe the conceptual framework for addressing residual CV risk with a focus on triglycerides and inflammation.
Texas A&M University College of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
DESIGNATIONTexas A&M University College of Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only credit commensurate with the extent of their participation in the activity.
Christie M. Ballantyne, MD, faculty for this educational activity has received grant support from: Abbott Diagnostic, Akcea, Amgen, Esperion, Ionis, Novartis, Regeneron, Roche Diagnostic, NIH, AHA and the ADA. Dr. Ballantyne has also served as a consultant for Abbott Diagnostics, Althera, Amarin, Amgen, Arrowheard, Astra Zeneca, Corvidia, Denka Seiken, Esperion, Genentech, Gilead, Matinas BioPharma, Inc. New Amsterdam, Novartis, Novo Nordisk, Pfizer, Regeneron, Roche Diagnostic, Sanofi-Synthelabo.
The relevant financial relationships listed have been mitigated.PLANNERS DISCLOSURES